Muscle loss in men with prostate cancer on hormone therapy
Official title: SArcopenia in Men with Prostate Cancer undergoing ADT (SAP-ADT)
Funded at Seattle Inst for Biomedical/clinical Res · NIH-11258962 · Data updated 2026-11-12
This project will follow men starting androgen deprivation (hormone) therapy for prostate cancer to track muscle loss, strength, and quality of life over 12 months.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Inst for Biomedical/clinical Res NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | January 12, 2024 |
| Project end | December 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $144,806 |
| NIH project number | 5R01CA279220-03 |
| Project ID | NIH-11258962 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with a diagnosis of prostate cancer who are about to start or have recently started androgen deprivation therapy and can attend study visits for 12 months.
✕Less likely to help
Men not receiving ADT, those with severe medical issues that prevent study procedures (such as muscle biopsy), or those unwilling to complete follow-up are unlikely to benefit from participation.
What this research studies
If you join, you'll be one of about 70 men who start ADT and will be followed with regular visits for a year. Researchers will measure body composition with scans, test muscle strength and walking ability, collect blood samples and optional muscle biopsies, and ask about symptoms and daily function. They will study biological pathways including mitochondrial changes and search for clinical measurements that predict who loses muscle. The team will also collect patient-reported quality-of-life information to better understand the lived experience of muscle loss during treatment.
Why it matters
Potential benefit: If successful, this work could help doctors predict who will lose muscle on ADT and guide future treatments to preserve strength and quality of life.
How similar studies have gone: Previous research has shown ADT commonly causes muscle loss but there are no approved drugs for sarcopenia and predicting who will develop it is still largely untested, so elements of this work are novel.
Where this research is happening
-
Seattle Inst for Biomedical/clinical Res
Seattle, United States Active
Researchers
- Principal investigator: Garcia, Jose M. — Seattle Inst for Biomedical/clinical Res
- Study coordinator: Garcia, Jose M.
Related research
Other NIH-funded projects on the same topics.
-
Understanding muscle loss in men with prostate cancer receiving hormone therapy
This study is looking at how losing muscle mass and strength affects men with advanced prostate cancer who are receiving hormone therapy, and it aims to find ways to better support these patients over the next year.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.